卡瑞丽珠单抗联合GP化疗在非小细胞肺癌中的应用价值

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (537 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Camrelizumab combined with GP chemotherapy in the treatment of non-small cell lung cancer (NSCLC). Methods A total of 62 patients with NSCLC admitted to Maanshan People’s Hospital of Anhui Province from June 2019 to February 2021 were selected as the research subjects, and they were divided into single group and combined group according to random drawing, with 31 cases in each group. The single group was treated with GP chemotherapy, and the combined group was treated with Camrelizumab combined with GP chemotherapy. Clinical effects of two groups were compared. The indexes of pulmonary function (forced vital capacity [FVC], forced expiratory volume in the first second [FEV1], maximum ventilation volume [MVV], and immune function (CD4+, CD3+, CD8+) were compared between two groups before treatment and six cycles of treatment. Results Clinical effect of combined group was better than that of single group, and the difference was statistically significant (P ＜ 0.05). Six cycles of treatment, FVC, FEV1, and MVV in two groups were higher than those before treatment, and those in combined group were higher than those in single group, the differences were statistically significant (P ＜ 0.05). Six cycles of treatment, the levels of CD4+ and CD3+ in two groups were higher than those before treatment, and the levels of CD8+ in two groups were lower than those before treatment (P ＜ 0.05), and the levels of CD4+ and CD3+ in combined group were higher than those in single group, and the level of CD8+ in combined group was lower than that in single group, the differences were statistically significant (P < 0.05). Conclusion Camrelizumab combined with GP chemotherapy has a significant effect in the treatment of NSCLC, and can improve the lung function and immune function of patients.

Key words： Carrelizumab GP chemotherapy Non-small cell lung cancer Lung function Immune function Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Lei1 CAO Qisheng1 WANG Yuqin1 HUANG Qi2

Cite this article:

CHEN Lei1 CAO Qisheng1 WANG Yuqin1 HUANG Qi2. Application value of Camrelizumab combined with GP chemotherapy in non-small cell lung cancer[J]. 中国医药导报, 2022, 19(20): 92-95.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I20/92

[1] 尚聪聪，张力.非小细胞肺癌免疫治疗进展[J].中国肿瘤临床，2018，45（4）：205-208.
[2] 晁志祥，秦西淳，贾才力，等.色素上皮衍生因子及其多肽对非小细胞肺癌增殖、凋亡及迁移的影响[J].中国肺癌杂志，2021，24（12）：829-837.
[3] 林川，李维玲，张静，等.支气管动脉介入栓塞序贯灌注化疗对晚期NSCLS患者的疗效及对其NLR、HIF-1α及VEGF等指标的影响评估[J].转化医学杂志，2021，10（6）：382-385.
[4] 陈俊晓，刘远远.调强放疗联合GP方案治疗Ⅲ期非小细胞肺癌患者的疗效分析[J].黑龙江医药科学，2021，44（4）：128-129.
[5] 裴晓俊.甲磺酸阿帕替尼联合吉西他滨+顺铂化疗对晚期非小细胞肺癌患者疾病缓解率及卡氏评分的影响[J].中国药物与临床，2020，20（8）：1349-1351.
[6] 刘仪.药物选择剂量分割顺序对放疗联合免疫治疗晚期非小细胞肺癌疗效的影响[J].中国肿瘤临床，2021，48（3）：157-161.
[7] 乔梦，蒋涛，赵沙，等.PD-1/PD-L1抑制剂联合其他方式治疗在非小细胞肺癌治疗中的研究进展[J].肿瘤，2017， 37（6）：663-669.
[8] 郭晶晶，牟迪，韩颖.Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展[J].中国肺癌杂志，2021，24（1）：49-55.
[9] Jonna S，Subramaniam DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer （NSCLC）：an update [J]. Discov Med，2019，27（148）：167-170.
[10] 中国临床肿瘤学会.中国临床肿瘤学会（CSCO）原发性肺癌诊疗指南（2018版）[J].肿瘤研究与临床，2018，30（12）：793-824.
[11] 吕厚宽，庄文辉，黄一桂，等.PD-1/PD-L1抑制剂治疗非小细胞肺癌的疗效及预后观察[J].癌症进展，2020， 18（3）：279-281.
[12] 陈晓峰，谈宇龙.胸腔镜下肺段切除术治疗非小细胞肺癌的研究现状与进展[J].中国肺癌杂志，2018，21（4）：296-299.
[13] 肖聃.尼妥珠单抗联合TP方案对Ⅲa～Ⅳ期非小细胞肺癌的疗效及免疫功能分析[J].中国药物与临床，2021， 21（23）：3878-3880.
[14] 郭浩，周淑妮，冉瑞智.吉非替尼联合培美曲塞和顺铂治疗晚期非小细胞肺癌的安全性和有效性[J].现代肿瘤医学，2019，27（5）：796-800.
[15] 王旋，崔立春，党升强.非小细胞肺癌放化疗联合靶向治疗对血清肿瘤标志物、免疫功能及Cyclin D3水平影响的相关研究[J].现代检验医学杂志，2021，36（4）：25-30.
[16] 张华，刘奎奎，施公航.参芪扶正注射液联合GP方案治疗非小细胞肺癌的近期疗效、免疫功能及远期生存研究[J].临床和实验医学杂志，2021，20（1）：28-31.
[17] 迟旭，刘丽姣，王野，等.复方斑蝥胶囊联合GP化疗治疗晚期非小细胞肺癌的效果[J].中国医药导报，2021， 18（5）：97-100，112.
[18] 贺明刚，李志华，王丹婷，等.GP方案化疗联合恩度治疗老年非小细胞肺癌的效果及对预后的影响研究[J].实用老年医学，2019，33（3）：277-280.
[19] 杨旭初，吕会艳，王怀璋，等.益气化瘀汤合沙参麦冬汤辅助化疗对气阴两虚型肺癌患者肿瘤控制率及机体状况的影响[J].实用药物与临床，2021，24（1）：38-42.
[20] 王佳慧，陈公琰.基于PD-1/PD-L1抑制剂的非小细胞肺癌免疫治疗预测标志物的研究进展[J].现代肿瘤医学，2021，29（10）：1822-1825.
[21] 周洁，吴强，许峰，等.PD-1/PD-L1和CTLA-4免疫检查点抑制剂在小细胞肺癌中的临床研究进展[J].临床肿瘤学杂志，2021，26（7）：649-656.
[22] 沈仕俊，王巧丽，杨金江，等.肿瘤突变负荷对PD-1/PD-L1抑制剂治疗非小细胞肺癌临床疗效预测的Meta分析[J].肿瘤防治研究，2021，48（3）：281-287.
[23] 王善贵，王传艳.化疗结合PD-1抑制剂治疗NSCLC的疗效及其对血清Cyfra21-1，MMP-9水平的影响[J].重庆医学，2021，50（2）：292-296.
[24] 王毅，权琳.培养曲塞与顺铂联合吉非替尼治疗对非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].东南国防医药，2020，22（1）：43-47.
[25] 裘飞峰，王凌飞，王喜，等.抗PD-1/PD-L1单抗治疗进展期非小细胞肺癌的效果及对肿瘤浸润T细胞密度及分布的影响[J].实用癌症杂志，2021，36（7）：1120-1122.